About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
AERI - Aerie Pharmaceutical...| Previous Close | $17.45 | Open | |
| Volume | Market Cap | 809.32M | |
| Yield | Last Dividend |
| Aerie Pharmaceuticals Announces Presenta... | 03/11/21 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Aerie Pharmaceuticals to Participate in ... | 03/11/21 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Aerie Pharmaceuticals Reports Fourth Qua... | 02/25/21 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals to Participate in ... | 02/22/21 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Aerie Pharmaceuticals to Announce Fourth... | 02/18/21 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Global Rho Kinase (Rho-Associated Coiled... | 02/11/21 |
| DUBLIN--(BUSINESS WIRE)--The "Rho Kinase (Rho-Associated Coiled-Coil Forming Protein Kinase or ROCK) Inhibitor - Pipeline Insight, 2020" drug pipeline... | |
| Rho Associated Protein Kinase 2 Market A... | 01/12/21 |
| Los Angeles United States: The global Rho Associated Protein Kinase 2 market is researched with great precision and in a comprehensive manner to help ... | |
| Aerie Pharmaceuticals Receives European ... | 01/11/21 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Global Glaucoma Disease Insights and Mar... | 12/14/20 |
| DUBLIN--(BUSINESS WIRE)--The "Glaucoma - Disease Insights and Market Forecasts to 2026" report has been added to ResearchAndMarkets.com's offering. "G... | |
| Aerie Pharmaceuticals Receives Positive ... | 11/13/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Aerie Pharmaceuticals to Participate in ... | 11/10/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Aerie Pharmaceuticals Reports Third Quar... | 11/05/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Ophthalmic Drugs Market With Top Players... | 11/04/20 |
| Ophthalmic drugs are sterile preparations designed to treat several eye disorders. These are used in the treatment of dry eye, age-related macular deg... | |
| Santen and Aerie Conclude Exclusive Lice... | 10/28/20 |
| OSAKA, Japan & DURHAM, N.C.--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (???Santen???) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, ???Aerie??... | |
| Aerie Pharmaceuticals to Announce Third ... | 10/27/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals (NASDAQ:AERI) Rati... | 10/24/20 |
| Aerie Pharmaceuticals (NASDAQ:AERI) was downgraded by investment analysts at BidaskClub from a ???hold??? rating to a ???sell??? rating in a report re... | |
| Aerie Pharmaceuticals (NASDAQ:AERI) Stoc... | 10/22/20 |
| Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) was up 5.8% during trading on Thursday . The stock traded as high as $9.75 and last traded at $9.68. Approxi... | |
| Aerie Pharmaceuticals (NASDAQ:AERI) Down... | 10/21/20 |
| Bank of America downgraded shares of Aerie Pharmaceuticals (NASDAQ:AERI) from a neutral rating to an underperform rating in a report issued on Monday,... | |
| The Daily Biotech Pulse: Prothena Progre... | 10/21/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20) Ail... | |
| Aerie Pharmaceuticals (NASDAQ:AERI) Rati... | 10/21/20 |
| Aerie Pharmaceuticals (NASDAQ:AERI) was downgraded by equities research analysts at Bank of America from a ???neutral??? rating to an ???underperform?... | |
| Aerie Pharmaceuticals Announces Acceptan... | 09/29/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Aerie Pharmaceuticals Announces U.S. Foo... | 09/15/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development ... | |
| Aerie Pharmaceuticals Reports Second Qua... | 08/06/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals to Announce Second... | 07/30/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals Appoints Peter J. ... | 06/11/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie (AERI) Up 1.9% Since Last Earnings... | 06/05/20 |
| Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. | |
| Aerie Pharmaceuticals Reports First Quar... | 05/06/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals to Present at the ... | 05/05/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals to Announce First ... | 04/29/20 |
| DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development a... | |
| Aerie Pharmaceuticals (AERI) Expected to... | 04/28/20 |
| Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key e... | |
| Date | 2021-02-25 (AMC) | Est. (EPS/Rev.) | ($0.73)/ 22.36M |
| Actual (EPS/Rev.) | $-0.79/ $24.68 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Small Cap Trader | James Bills | 54.00 % | Follow |
| Symmetry Options | Symmetry Options | 33.00 % | Follow |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
| OptionAdvantage | OptionAdvantage | 0.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
